BioPharmSignal logoBioPharmSignal

Biotech News

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

Seer, Inc (SEER)Seer, IncEarnings

REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended June 30, 2026. Recent Highlights Achieved revenue of $3.1

Related news

SEERSeer, Inc2026-05-13 20:05 EST

Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

SEERSeer, Inc2026-02-26 21:05 EST

Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

View all latest news

Seer, Inc

Deep Proteomics Company Seer develops tools for large-scale, unbiased analysis of the proteome across research, translational medicine, and drug development. Proteograph Product Suite The Proteograph platform combines engineered nanoparticles, automated sample processing, consumables, and analytical software to capture proteins across a...

Recent company news

SEERSeer, Inc2026-08-11 20:05 EST

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

SEERSeer, Inc2026-08-03 20:15 EST

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

SEERSeer, Inc2026-08-03 20:05 EST

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

SEERSeer, Inc2026-07-30 21:30 EST

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

SEERSeer, Inc2026-07-28 21:40 EST

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

Stock data

Close
2.03 USD
Market cap
102.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States